Vertex Pharmaceuticals

Traded on the St. Petersburg Stock Exchange
Vertex Pharmaceuticals is a large American pharmaceutical company founded in 1989. He is engaged in the development of medicines for the treatment of rare genetic diseases. The only manufacturer of drugs for the treatment of cystic fibrosis. The headquarters are kept in Massachusetts.
Vertex Pharmaceuticals stock price chart
vol.
change
P/E adj.
Net profit (adj.)
P/B
Book value
P/FCF
FCF
Yield
Growth potential

Vertex Pharmaceuticals balance sheet

Report period2018 2019 2020 2021 2022 Q3 23
End date of the reporting period
Capitalization, $
Capitalization, $
Enterprise Value
Book Value
Shareholders Book Value
Current liabilities
Noncurrent liabilities
Total liabilities
Debt
Cash and cash equivalents
Net debt
Assets
Total ordinary shares
Ordinary share price

Vertex Pharmaceuticals cash flows

Report period2018 2019 2020 2021 2022 Q3 23 TTM
End date of the reporting period
Sales
Gross profit
Operation Income
Earnings
Shareholders earnings
Adjusted Earnings
EBITDA
Operation Cashflow
Capital expenditure
Free Cash Flow
EPS
Adjusted EPS

Vertex Pharmaceuticals multipliers

Report period2018 2019 2020 2021 2022 Q3 23 TTM
P/E
P/E adj.
E/P
E adj./P
P/B
P/S
P/FCF
L/A
Debt-To-Equity
Net Debt/EBITDA
EV/EBITDA

Vertex Pharmaceuticals profitability

Report period2018 2019 2020 2021 2022 Q3 23 TTM
ROA
ROE
ROS
Gross margin
EBITDA Margin
Operating margin
Vertex Pharmaceuticals assets
Vertex Pharmaceuticals cash flows

Vertex Pharmaceuticals shares

TickerNameTypeNominal valueISINPrice
VRTX:USVertex Pharmaceuticals IncorporatedCommon share-US92532F1003$449.8
VRTX-RM:RMVertex PharmaceuticalsCommon share$0.25US92532F1003RUB 7,563
Vertex Pharmaceuticals news
07.11.2023
Vertex Pharmaceuticals' GAAP net income for 9 months of 2023 was $2.651 billion, up 5.9% from $2.503 billion in the prior year. Revenue increased 10.9% to $7.352 billion compared to $6.628 billion a year earlier.
Source: investors.vrtx.com pictogram investors.vrtx.com
Pictogram next
08.02.2023
Vertex Pharmaceuticals' GAAP net income for 2022 was $3.322 billion, up 41.8% from $2.342 billion in the previous year. Revenues increased 17.9% to $8.931 billion from $7.574 billion a year earlier.
Source: investors.vrtx.com pictogram investors.vrtx.com
Pictogram next
28.10.2022
Vertex Pharmaceuticals' GAAP net income for 9 months of 2022 was $2.503 billion, up 59.2% from $1.572 billion in the previous year. Revenue increased 20.5% to $6.628 billion from $5.502 billion a year earlier.
Source: investors.vrtx.com pictogram investors.vrtx.com
Pictogram next
05.08.2022
Vertex Pharmaceuticals' GAAP net income for 6 months of 2022 was $1.573 billion, up twofold from $0.72 billion in the previous year. Revenue increased 22.1% to $4.294 billion from $3.518 billion a year earlier.
Source: investors.vrtx.com pictogram investors.vrtx.com
Pictogram next
All Vertex Pharmaceuticals news
General information
Company nameVertex Pharmaceuticals
Tags#biotechnology, #katie wood's choice, #s&p500 index
SectorHealth Care / Pharmaceuticals, Biotechnology & Life Sciences / Biotechnology / Biotechnology
Business address50 NORTHERN AVENUE BOSTON MA 02210 6173416393
Mailing address50 NORTHERN AVENUE BOSTON MA 02210
Websitewww.vrtx.com
Information disclosurewww.sec.gov